Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 20 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q2 2024
Institutional positions in Pharvaris N.V. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 36
- +1 vs. Q1 2024
- Shares held
- 43.0M
- +583.0K (+1.4%) vs. Q1 2024
- Total value
- $808.6M
- −$171.9M (−17.5%) vs. Q1 2024
- New holders
- 5
- 10 more added
- Sold out
- 4
- 9 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| General Atlantic LLC | 7,531,252 | $141.6M | 4.45% | 00.0% | Unchanged |
| FMR LLC | 5,205,656 | $97.9M | 0.01% | +12,672+0.2% | Added |
| Foresite Capital Management IV, LLC | 4,293,854 | $80.7M | 54.23% | +255,012+6.3% | Added |
| venBio Partners LLC | 4,289,304 | $80.6M | 34.83% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,653,310 | $68.7M | 0.26% | 00.0% | Unchanged |
| VR Adviser, LLC | 3,395,606 | $63.8M | 4.07% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 3,303,381 | $62.1M | 6.82% | 00.0% | Unchanged |
| Commodore Capital LP | 1,810,175 | $34.0M | 2.32% | +85,175+4.9% | Added |
| Novo Holdings A/S | 1,725,000 | $32.4M | 1.75% | +556,970+47.7% | Added |
| Cormorant Asset Management, LP | 1,466,460 | $27.6M | 1.60% | −245,000−14.3% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 1,397,279 | $26.3M | 0.44% | +335,687+31.6% | Added |
| EcoR1 Capital, LLC | 900,000 | $16.9M | 0.52% | 00.0% | Unchanged |
| 5AM Venture Management, LLC | 797,600 | $15.0M | 3.35% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 756,931 | $14.2M | 0.43% | +4,007+0.5% | Added |
| Sofinnova Investments, Inc. | 601,534 | $11.3M | 0.71% | +16,862+2.9% | Added |
| Price T Rowe Associates Inc | 585,271 | $11.0M | 0.00% | −172,644−22.8% | Reduced |
| Sphera Funds Management Ltd. | 403,265 | $7.58M | 1.24% | +10,388+2.6% | Added |
| Soleus Capital Management, L.P. | 399,430 | $7.51M | 0.66% | −2,471−0.6% | Reduced |
| TD Asset Management Inc | 85,816 | $1.61M | 0.00% | −26,800−23.8% | Reduced |
| Goldman Sachs Group Inc | 61,470 | $1.16M | 0.00% | +30,354+97.6% | Added |
| Manufacturers Life Insurance Company, The | 55,078 | $1.04M | 0.00% | 00.0% | Unchanged |
| Marshall Wace, LLP | 51,168 | $962.0K | 0.00% | −7,001−12.0% | Reduced |
| Walleye Capital LLC | 48,768 | $916.8K | 0.01% | −48,414−49.8% | Reduced |
| Millennium Management LLC | 38,945 | $732.2K | 0.00% | +18,418+89.7% | Added |
| HealthInvest Partners AB | 34,328 | $645.4K | 0.39% | +34,328 | New |
| Geode Capital Management, LLC | 31,224 | $587.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 23,296 | $438.0K | 0.00% | −5,745−19.8% | Reduced |
| HighVista Strategies LLC | 16,750 | $314.9K | 0.12% | 00.0% | Unchanged |
| Y-Intercept (Hong Kong) Ltd | 15,883 | $298.6K | 0.02% | +15,883 | New |
| Citadel Advisors LLC | 14,472 | $272.1K | 0.00% | −223,833−93.9% | Reduced |
| Bank of America Corp | 6,121 | $115.1K | 0.00% | −1,687−21.6% | Reduced |
| Virtus ETF Advisers LLC | 5,001 | $94.0K | 0.05% | +5,001 | New |
| BlackRock Inc. | 2,268 | $42.6K | 0.00% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 2,000 | $37.6K | 0.01% | 00.0% | Unchanged |
| Wells Fargo & Company | 700 | $13.2K | 0.00% | +700 | New |
| UBS Group AG | 167 | $3.14K | 0.00% | +167 | New |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −30,138−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −20,018−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −11,700−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −3,150−100.0% | Sold out |